Outline of the Report

1. Basic Information
2. Honorary Editors-in-Chief
3. Editors-in-Chief
4. Editorial Board Members
5. Publication: Number, Article Types, Internationality
7. Journal Impact Factor
8. Website Visits
9. Most Cited Articles in 2021
10. Special Series Published in 2021
11. Reviewers of the Month (2021)
12. Introduction of the Publisher AME
1. Basic Information

- Open Access
- Peer Reviewed
- Launched in March 2012
- **Impact Factor: 6.498**
- Indexed by Science Citation Index Expanded (SCIE), PubMed/PubMed Central, Scopus, Google Scholar, Medscape, Chemical Abstracts Service (CAS) Databases, MDlinx
- The first international journal focusing on closing the gap between “Bench and Bedside” in lung cancer and related thoracic diseases.
1. Basic Information

TLCR is the official publication of:

• General Hospital of Eastern Theater Command, Nanjing, China
• Society for Translational Medicine (STM), Hong Kong

TLCR is endorsed by:

• Spanish Lung Cancer Group (SLCG)
• Bonnie J. Addario Lung Cancer Foundation (ALCF)
• Brazilian Society of Thoracic Surgery (SBCT)
2. Honorary Editors-in-Chief

Fred R. Hirsch, MD, PhD
Center for Thoracic Oncology, Tisch Cancer Institute at Mount Sinai, USA

Yi-Long Wu
Guangdong General Hospital & Guangdong Academy of Medical Sciences, China
3. Editors-in-Chief

Yong Song, MD, PhD
General Hospital of Eastern Theater Command, China

Caicun Zhou, MD, PhD
Shanghai Pulmonary Hospital, China

Rafael Rosell, MD, PhD
Dexeus University Institute, Spain
4. Editorial Board Members

111 in totality, including:

- Two Honorary Editors-in-Chief
- Three Editors-in-Chief
- Four Associate Editors-in-Chief
- One Editor Emeritus
- Two Associate Editor
- 99 Editorial Board Members
Till Dec 31, 2021, totally 1664 articles were published in TLCR.

The number of publication was increased from 2012-2014, yet it has kept a stability between 2014 and 2017, and has an obvious growth from 2018 to 2021 to meet the development of the journal as a monthly journal.
5. Publication: Diverse Article Types

TLCR embraces diverse article types to meet demands from international authors and readers. The major article types published in TLCR include Original Article, Review Article and Editorial.

- Original Article: 60%
- Review Article: 25%
- Editorial: 5%
- Case Report: 4%
- Editorial Commentary: 3%
- Consensus: 1%
- Letter to the Editor: 1%
- Others: 1%
In total, 412 Corresponding Authors from 28 countries and regions contributed to TLCR in 2021, with the majority from China, USA and Japan.
This year, retrieval number of TLCR in PMC has reached up to a total of 784,842 times.
7. Journal Impact Factor

2020 Journal Impact Factor & percentile rank in category for: Translational Lung Cancer Research

Source: Web of Science Core Collection  Updated on Dec 31, 2021
According to the data collected from Google Analytics, there are altogether 246,482 users and 683,028 pageviews in 2021. Readers who visited TLCR website form diverse countries, with the majority from United States, followed by China, India, United Kingdom and Japan.

Source: Google Analytics  Jan 1, 2021 - Dec 31, 2021
## 9. Most Cited Articles in 2021

<table>
<thead>
<tr>
<th>Corresponding Author</th>
<th>Article Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shaker A. Mousa</td>
<td>Non-small cell lung cancer: current treatment and future advances</td>
</tr>
<tr>
<td>Brett G.M. Hughes</td>
<td>Targeted therapy for non-small cell lung cancer: current standards and the promise of the future</td>
</tr>
<tr>
<td>Farhad Islami</td>
<td>Global trends of lung cancer mortality and smoking prevalence</td>
</tr>
<tr>
<td>Jeryl Villadolid</td>
<td>Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities</td>
</tr>
<tr>
<td>Alberto Ruano-Ravina</td>
<td>The epidemiology of lung cancer</td>
</tr>
<tr>
<td>Ming-Sound Tsao</td>
<td>Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review</td>
</tr>
<tr>
<td>Hidetaka Uramoto</td>
<td>Recurrence after surgery in patients with NSCLC</td>
</tr>
<tr>
<td>Takashi Kohno</td>
<td>Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer</td>
</tr>
<tr>
<td>Jyoti Malhotra</td>
<td>Current state of immunotherapy for non-small cell lung cancer</td>
</tr>
<tr>
<td>Po Yee Yip</td>
<td>Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer</td>
</tr>
</tbody>
</table>

Source: Web of Science Core Collection  Updated on Dec 31, 2021
10. Special Series Published in 2021

“New Era of Treatment for Unresectable Locally Advanced Non-Small Cell Lung Cancer” edited by

Zhengfei Zhu, MD
Fudan University Shanghai Cancer Center, China

Xiaolong Fu
Shanghai Chest Hospital, China

Steven H. Lin, MD, PhD
The University of Texas MD Anderson Cancer Center, USA
10. Special Series Published in 2021

“Oligometastatic NSCLC: Definition and Treatment Opportunities” edited by

Maurizio V. Infante, MD
University and Hospital Trust, Verona, Italy

Thierry Berghmans, MD, PhD
Institute Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
10. Special Series Published in 2021

“Immunotherapy in Other Thoracic Malignancies and Uncommon Populations”
edited by

Jordi Remon, MD
Hospital HM Delfos, HM
Hospitales, Barcelona, Spain

Benjamin Besse, MD, PhD
Université Paris-Saclay, Villejuif,
France
10. Special Series Published in 2021

“Lung Cancer and The Immune System” edited by

Daniel Steinfort, MBBS, BMedSci, FRACP, PhD
University of Melbourne,
Melbourne, Australia
10. Special Series Published in 2021

- “Lung cancer screening” edited by

Paul Van Schil, MD, PhD
Antwerp University Hospital, Antwerp, Belgium

Annemiek Snoeckx, MD, PhD
Antwerp University Hospital, Antwerp, Belgium
10. Special Series Published in 2021

➢ “Radiotherapy in thoracic malignancies” edited by

Jacek Jassem, MD, PhD
Medical University of Gdańsk, Gdańsk, Poland.

Rafal Dziadziuszko, MD, PhD
Medical University of Gdańsk, Gdańsk, Poland.
10. Special Series Published in 2021

➤ “Implementation of CT-based screening of lung cancer” edited by

Witold Rzyman, MD, PhD
Medical University of Gdansk,
Gdańsk, Poland
10. Special Series Published in 2021

“Multimodal Management of Locally Advanced N2 Non-small Cell Lung Cancer” edited by

Mariano Provencio, MD, PhD
Hospital Universitario Puerta de Hierro, Madrid, Spain
“Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions” edited by

Silvia Novello, MD, PhD
University of Turin, San Luigi Hospital, Orbassano, Italy

Francesco Passiglia, MD, PhD
University of Turin, San Luigi Hospital, Orbassano, Italy
11. Reviewers of the Month (2021)

In 2021, many TLCR reviewers have made outstanding contributions to the peer review process. Hereby, we would like to highlight a few of them as follows in form of interview. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

**January, 2021**
- Sung Yong Lee, University Guro Hospital, Korea
- Michael Pritchett, FirstHealth of the Carolinas & Pinehurst Medical Clinic, USA

**February, 2021**
- Mizuho Nishio, Kobe University Hospital, Japan
- Ernest Nadal, Catalan Institute of Oncology, Spain

**March, 2021**
- Petros Christopoulos, Heidelberg University Hospital, Germany
- Kang-Yi Su, National Taiwan University, Taiwan
- Menno Tamminga, University of Groningen, the Netherlands

**April, 2021**
- Kyoji Hirai, Nippon Medical School Chiba Hokusoh Hospital, Japan
- Artur Mezheyevskiy, Uppsala University, Sweden
- Alexander Gill, Johns Hopkins University, USA
- Muhammad Zubair Afzal, Norris Cotton Cancer Centre, USA
11. Reviewers of the Month (2021)

In 2021, many TLCR reviewers have made outstanding contributions to the peer review process. Hereby, we would like to highlight a few of them as follows in form of interview. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

May, 2021
Masahide Oki, National Hospital Organization Nagoya Medical Center, Japan
Yasushi Shintani, Respiratory Center in the Osaka University Hospital, Japan
Taichiro Goto, Yamanashi Central Hospital, Japan
Pierre-Jean Lamy, Imagenome Montpellier, France

June, 2021
Rafael Rosell, Germans Trias i Pujol Research Institute and Hospital, Spain
Taiki Hakozaki, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

July, 2021
Florian Eichhorn, Thoraxklinik Heidelberg University Hospital, Germany

August, 2021
Wolfgang M. Brueckl, University of Erlangen-Nuremberg, Germany
Kadoaki Ohashi, Okayama University Hospital, Japan
Ukhyun Jo, National Cancer Institute, National Institutes of Health, USA
Martin P. Barr, Trinity St James’s Cancer Institute, Ireland
11. Reviewers of the Month (2021)

In 2021, many TLCR reviewers have made outstanding contributions to the peer review process. Hereby, we would like to highlight a few of them as follows in form of interview. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

September, 2021
Rui Haddad, Pontifical Catholic University of Rio de Janeiro, Brazil
Per Hydbring, the Karolinska Institutet, Sweden
Ajay Wagh, University of Chicago, USA

October, 2021
Akira Ono, Shizuoka Cancer Center, Japan
Yeul Hong Kim, Korea University, Korea

November, 2021
Umberto Malapelle, University Federico II of Naples, Italy
Hae-Seong Nam, Inha University Hospital, Korea
Lukas Käsmann, Ludwig Maximilian University, Germany
Yuji Matsumoto, National Cancer Center Hospital, Japan
Dwight Owen, The Ohio State University, USA
12. Introduction of the Publisher AME

Meet our Publisher:

**AME Publishing Company**

- Established in 2009
- Registered in Hong Kong
- 10 offices around the world

- 60+ peer-reviewed journals
  - 13 indexed in SCIE
  - 20 indexed in PubMed/PMC/MEDLINE

- 200+ Medical Books
  - 80+ Medical Books in English
  - 120+ Medical Books in Chinese
- 150+ Electronic Editions
Thank You for All Your Support!